1. Home
  2. Live Updates
  3. New animal drug

New Animal Drug News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from New animal drug. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In New Animal Drug Today - Breaking & Trending Today

AbCellera Reports Full Year 2023 Business Results

Total revenue of $38 million, compared to $485 million in FY 2022Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the yearNet loss of $0.51 per share on a basic and diluted basis, compared to earnings of $0.56 (basic) and $0.50 (diluted) per share in 2022VANCOUVER, Brit. ....

United Kingdom , British Columbia , Kathleen Reid , Carl Hansen , Murray Mccutcheon , Abcellera Biologics Inc , Research Development Rd Expenses , Business Development , Exchange Commission , Investor Relations , Key Business , Annual Report , Investigational New Drug , New Animal Drug , Private Securities Litigation Reform Act , Financial Condition , Comprehensive Income , Melanie Solomon ,

Dorothy Bailey to lead FDA's Office of Minor Use and Minor Species

Dr. Bailey has been part of the OMUMs staff since 2008. ....

United States , Sweet Briar College , Meg Oeller , Dorothy Bailey , Office Of New Animal Drug Evaluation , Maryland Regional College Of Veterinary Medicine , Clemson University , Drug Administration , Antimicrobial Drugs Team , Division Of Therapeutic Drugs For Food Animals , Office Of Minor , Minor Use , Minor Species , Veterinary Medicine , Acting Director , Legally Marketed Unapproved New Animal Drugs , Therapeutic Drugs , Food Animals , New Animal Drug , Virginia Maryland Regional College , Sweet Briar ,

AbCellera Reports Q3 2023 Business Results

Total revenue of $7 million, compared to $101 million in Q3 2022Total cumulative partnered program starts of 110, up 20% from Q3 2022Net loss of $0.10 per share on a basic and diluted basis, compared to net earnings of $0.09 and $0.08 per share on a basic and diluted basis, respectively, in Q3 2022VANCOUVER, British. ....

British Columbia , United Kingdom , Murray Mccutcheon , Carl Hansen , Josephine Hellschlienger , Jessica Yingling , Exchange Commission , Abcellera Biologics Inc , Research Development Rd Expenses , Business Development , Investor Relations , Key Business , Investigational New Drug , New Animal Drug , Private Securities Litigation Reform Act , Financial Condition , Consolidated Statements , Consolidated Statement ,

Viewpoint: No, DNA is NOT a drug—Why the FDA's continued insistence to regulate gene edited research animals as drugs blocks US-based innovation

Investigational research animals that have been genome edited CANNOT enter the food supply in the United States irrespective of the edits they carry, ....

United States , Allison Van Eenennaam , Division Of Animal , National Environmental Policy , New Animal Drug , Allison Van , National Environmental Policy Act , Animal Drug User Product ,

FDA's animal biotech regulatory process slows innovation | Agri-Pulse Communications, Inc.

The Food and Drug Administration has taken baby steps in helping advance approvals of gene-edited animals for food production; however, the insistence by FDA that changing an animal’s DNA is a “drug” and out of USDA’s purview could keep innovation decades away from producer adoption.  ....

United States , Washington State University , Jon Oatley , Andrew Bailey , Joe Biden , Van Eenennaam , Alison Van Eenennaam , School Of Molecular Biosciences , Genomics Initiative , National Pork Producers Council , Washington State University College Of Veterinary Medicine , University Of California , Drug Administration , House Agriculture Committee , Molecular Biosciences , Veterinary Medicine , Washington State , New Animal Drug , New Animal Drug Application , President Joe Biden , Animal Biotechnology , Gene Editing Technology ,